NASDAQ · PRME

Prime Medicine, Inc.

Healthcare · Biotechnology

$3.13▼ 0.48% ($0.02)today

As of 10:24 AM ET

52-week

$2.67$6.94

Market cap

$564.43M

P/E

-2.84

EPS (TTM)

-$1.06

Next earnings

Nov 6, 2026

No multiple

Valuation

Recommended · Earnings yield

Price used

$3.13

Earnings yield

Unavailable

Reported earnings

10-year Treasury benchmark: 5%

USD · Financial statements through 2026-06-30 · EPS source period not supplied

A positive earnings figure and a usable price are needed to calculate earnings yield.

Method, dates & sources

Earnings per share divided by the price used, compared with the 10-year Treasury rate.

Price timestamp: Sep 18, 2026, 2:24 PM UTC
Financial statement period: Financial statements through 2026-06-30 · EPS source period not supplied
Data refreshed: Sep 18, 2026, 2:24 PM UTC · provider

Why this method?

The company is still too young and does not have a stable, multi-year FCFF base. Use EV/Revenue multiples and comparable transactions instead of a DCF.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Is there enough operating history to anchor a DCF? Only 4 years of public or statement history are available, so multiples are more decision-useful than a DCF here.

Price vs Fundamentals

Why The Stock Is Moving

Likely fundamental deteriorationModerate confidence

1Y Price: -32.47%Revenue (TTM): -17.9%FCF (TTM): -46.59%

What changed

The stock fell 32.47% over the last year. Revenue declined 17.9% over the trailing twelve months. Operating margin moved from -4,116.57% to -4,824.94%. Free cash flow declined 46.59% over the trailing twelve months.

What the market seems to be pricing

The market appears to be responding to weaker operating momentum rather than only rerating the stock.

What would invalidate this read

Operating margin stands at -4,824.94%. Revenue declined 17.9% — this read reverses if that trend stabilizes. Free cash flow fell 46.59% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.

Performance

Return analysis

Company profile

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology.

CEOAllan Reine

SectorHealthcare

IndustryBiotechnology

Employees146

IPO dateOct 20, 2022

https://www.primemedicine.com

Market multiples

Forward P/E—

EV/EBITDA-2.91

Enterprise value$569.59M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth3.5%

Gross margin (FY2025)-58.05%▼158.1ppvs FY2024

Operating margin (FY2025)-4,498.06%▲2289.3ppvs FY2024

ROEN/A

Analyst consensus

RatingBuy

Target price$7.50▲140.00%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 6, 2026

Q4 FY26 · EPS est -$0.23 · Revenue est $1.32M

View

NASDAQ · PRME

Prime Medicine, Inc.

Healthcare · Biotechnology

$3.13▼ 0.48% ($0.02)today

As of 10:24 AM ET

52-week

$2.67$6.94

Market cap

$564.43M

P/E

-2.84

EPS (TTM)

-$1.06

Next earnings

Nov 6, 2026

No multiple

Valuation

Recommended · Earnings yield

Price used

$3.13

Earnings yield

Unavailable

Reported earnings

10-year Treasury benchmark: 5%

USD · Financial statements through 2026-06-30 · EPS source period not supplied

A positive earnings figure and a usable price are needed to calculate earnings yield.

Method, dates & sources

Earnings per share divided by the price used, compared with the 10-year Treasury rate.

Price timestamp: Sep 18, 2026, 2:24 PM UTC
Financial statement period: Financial statements through 2026-06-30 · EPS source period not supplied
Data refreshed: Sep 18, 2026, 2:24 PM UTC · provider

Why this method?

The company is still too young and does not have a stable, multi-year FCFF base. Use EV/Revenue multiples and comparable transactions instead of a DCF.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Is there enough operating history to anchor a DCF? Only 4 years of public or statement history are available, so multiples are more decision-useful than a DCF here.

Price vs Fundamentals

Why The Stock Is Moving

Likely fundamental deteriorationModerate confidence

1Y Price: -32.47%Revenue (TTM): -17.9%FCF (TTM): -46.59%

What changed

What the market seems to be pricing

The market appears to be responding to weaker operating momentum rather than only rerating the stock.

What would invalidate this read

Performance

Return analysis

Company profile

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology.

CEOAllan Reine

SectorHealthcare

IndustryBiotechnology

Employees146

IPO dateOct 20, 2022

https://www.primemedicine.com

Market multiples

Forward P/E—

EV/EBITDA-2.91

Enterprise value$569.59M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth3.5%

Gross margin (FY2025)-58.05%▼158.1ppvs FY2024

Operating margin (FY2025)-4,498.06%▲2289.3ppvs FY2024

ROEN/A

Analyst consensus

RatingBuy

Target price$7.50▲140.00%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 6, 2026

Q4 FY26 · EPS est -$0.23 · Revenue est $1.32M

View